Inventor · disambiguated record
Hua Zhu Ke
Also filed as: KE HUA Z · KE HUA ZHU
16 granted patents·11 pending applications·197 citations·filing 1996–2023
94Inventor score
Files withPFIZER10AMGEN INC9ANGITIA BIOPHARMACEUTICALS GUANGZHOU LTD1CAMERON KIMBERLY O1LI XIAODONG1
Top patents by PatentIndex Score
27 records- 0190US6153622AEstrogen agonists/antagonistsPFIZER·Filed 1998·Granted Nov 28, 2000·59 cites·25 claims
- 0285US6649657B2Prevention of loss and restoration of bone mass by certain prostaglandin agonistsPFIZER·Filed 2002·Granted Nov 18, 2003·16 cites·49 claims
- 0382US9657090B2Method of treating alveolar bone loss through the use of anti-sclerostin antibodiesAMGEN INC·Filed 2012·Granted May 23, 2017·5 cites·16 claims
- 0482US6441193B1Estrogen agonists/antagonistsPFIZER·Filed 1999·Granted Aug 27, 2002·28 cites·3 claims
- 0581US10538584B2Methods for treating bone gap defectsLI XIAODONG·Filed 2012·Granted Jan 21, 2020·4 cites·14 claims
- 0680US9913900B2Method of treating alvelor bone loss through the use of anti-sclerostin antibodiesAMGEN INC·Filed 2017·Granted Mar 13, 2018·2 cites·16 claims
- 0779US6492412B2Prevention of loss and restoration of bone mass by certain prostaglandin agonistsPFIZER·Filed 2001·Granted Dec 10, 2002·9 cites·104 claims
- 0877US7255984B2Combination therapy for osteoporosisPFIZER·Filed 2000·Granted Aug 14, 2007·9 cites·41 claims
- 0976US9879072B2DKK1 antibodies and methods of useRICHARDS WILLIAM GLEASON·Filed 2011·Granted Jan 30, 2018·4 cites·16 claims
- 1076US6288120B1Prevention of loss and restoration of bone mass by certain prostaglandin agonistsPFIZER·Filed 1997·Granted Sep 11, 2001·30 cites·124 claims
- 1170US12297260B2DKK1 antibodies and methods of useAMGEN INC·Filed 2020·Granted May 13, 2025·0 cites·12 claims
- 1270US2024400664A1Anti-Sclerostin Antibodies and Their Use to Treat Bone Disorders as Part of a RegimenAMGEN INC·Filed 2023·Application pending·0 cites
- 1368US6998423B2Prevention of loss and restoration of bone mass by certain prostaglandin agonistsPFIZER·Filed 2003·Granted Feb 14, 2006·2 cites·36 claims
- 1466US2020115444A1Methods for treating bone gap defectsAMGEN INC·Filed 2019·Application pending·0 cites
- 1565US10800839B2DKK1 antibodies and methods of useAMGEN INC·Filed 2017·Granted Oct 13, 2020·0 cites·8 claims
- 1665US6323232B1Combination therapy for osteoporosisPFIZER·Filed 1996·Granted Nov 27, 2001·17 cites·2 claims
- 1757US6426359B1Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonistsPFIZER·Filed 1997·Granted Jul 30, 2002·12 cites·19 claims
- 1857US2007191319A1Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogenPFIZER·Filed 2004·Application pending·0 cites
- 1957US2010317712A1Estrogen Agonists/Antagonists For Preventing Breast CancerCAMERON KIMBERLY O·Filed 2010·Application pending·0 cites
- 2054US2018169234A1Method of Treating Alvelor Bone Loss Through The Use of Anti-Sclerostin AntibodiesAMGEN INC·Filed 2018·Application pending·0 cites
- 2154US2002132816A1Estrogen agonists/antagonists for preventing breast cancerFiled 2002·Application pending·0 cites
- 2252US2001025051A1Estrogen agonists/antagonists for preventing breast cancerFiled 2001·Application pending·0 cites
- 2351US2011044978A1Method for treating bone fractureAMGEN INC·Filed 2008·Application pending·0 cites
- 2449US2023312755A1Anti-sclerostin constructs and uses thereofANGITIA BIOPHARMACEUTICALS GUANGZHOU LTD·Filed 2022·Application pending·0 cites
- 2548US11851483B2Anti-sclerostin antibodies and their use to treat bone disorders as part of a regimenAMGEN INC·Filed 2015·Granted Dec 26, 2023·0 cites·13 claims
- 2641US2009118316A1Methods for Augmenting BonePFZER INC·Filed 2005·Application pending·0 cites
- 2739US2008045504A1Benzonitrile Derivatives to Treat Musculoskeletal FrailtyPFIZER PROD INC·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Hua Zhu Ke files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →